The percentage increase in HE4 values has been used as an aid in monitoring recurrence or progressive disease in patients with invasive epithelial ovarian cancer. Currently there is no clinically accepted cut-off for use in monitoring cancer progression in epithelial ovarian cancer subjects with this assay. Serial testing for patient HE4 assay values should be used in conjunction with methods used for monitoring ovarian cancer.
1.0 mL Serum from a Red Top Tube in a Plastic Vial
48 hours Ambient
72 hours Refrigerated
28 days Frozen
Sample collected must be allowed to clot for at least 30 minutes but no longer than 1 hour
0.3 mL Serum
| Female Premenopausal | ≤70 pmol/L |
| Female Postmenopausal | ≤140 pmol/L |
Limitations: A clinical study indicated that serial HE4 levels correlated with clinical status (progression vs. no progression) in 70% (247/354) of the study participants.
The percentage increase in HE4 values has been used as an aid in monitoring recurrence or progressive disease in patients with invasive epithelial ovarian cancer. Currently there is no clinically accepted cut-off for use in monitoring cancer progression in epithelial ovarian cancer subjects with this assay. Serial testing for patient HE4 assay values should be used in conjunction with methods used for monitoring ovarian cancer.
3 to 6 days
00913333
86305